Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

59.89 USD UNCHANGED
Streaming Delayed Price Updated: 4:26 AM EST, Nov 24, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Johanna Mercier, Chief Commercial Officer, and Merdad Parsey, MD, PhD, Chief Medical Officer, will participate in a fireside chat at the 3rd... 
From Business Wire News Releases
Noteworthy Monday Option Activity: GILD, CBRL, VMW
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Gilead Sciences Inc (GILD), where a total of 48,807 contracts have traded so far,... 
Tags Stocks
From Market News Video
Better Buy: Gilead Sciences vs. Pfizer
Both drugmakers are at critical crossroads with new COVID-19 programs. Which has the stronger prospects? 
Tags GILD MRK PFE
From Motley Fool
Could Sorrento Therapeutics Be a Millionaire-Maker Stock?
Sorrento may be close to commercialization of coronavirus tests -- joining many rivals. 
Tags ABT LLY GILD
From Motley Fool
This Company's New Approach Could Slash Gilead's Profit From HIV Drugs
The company's HIV franchise faces threats from many different directions. 
Tags GILD SGMO Market News
From Motley Fool
Is There Room for Latecomers to the COVID-19 Party?
Despite multiple treatments, vaccines, and tests for COVID-19 developed by leading competitors, Sorrento's CEO Henry Ji thinks the company still has an opportunity to thrive. 
Tags PFE BNTX LLY
From Motley Fool
WHO Recommends Against Using Gilead's Remdesivir for COVID-19
The agency concluded there's no evidence that the drug improves survival or positively impacts other outcomes. 
Tags GILD Market News
From Motley Fool
Pharma Sector Did Its Job With COVID-19 Vaccine: Barclays Analyst
The pharmaceutical industry has succeeded in doing its job in manufacturing multiple vaccines for the novel coronavirus, and it's ... 
Tags MRNA Market News Analyst Ratings
From Benzinga
Cross The Aisle
The odds against another bailout have increased after Treasury Secy. Mnuchin said the Fed would not get treasury funding. 
Tags Stocks / Equities
From Blogs - TalkMarkets
IBB, GILD, VRTX, REGN: ETF Outflow Alert
Symbols mentioned in this story: IBB, GILD, VRTX, REGN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
Coronavirus update: U.S. moves closer to 200,000 cases a day; Birx and Fauci urge Americans to follow safety measures over Thanksgiving
The global case tally for the coronavirus illness COVID-19 climbed above 57 million on Friday, and the U.S. moved closer to 200,000 cases in a day and set a fresh record for hospitalizations as the... 
Tags Health/Care General Biotechnology
From MarketWatch
The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ... 
Tags VCYT ALXO AMGN
From Benzinga
Stock-index futures mixed as COVID restrictions threaten recovery
Stock-index futures trade mixed Friday as rising COVID-19 cases raise doubts about the prospects for the economic recovery. The Treasury Department's decision to allow emergency Federal Reserve... 
Tags MRNA FL NQ00
From MarketWatch
Is Sorrento Therapeutics Stock a Buy?
Its COVID-19 programs have helped the stock rally this year, but they could also be its undoing if they fall through. 
Tags JNJ GILD SRNE
From Motley Fool
A Peek Into The Markets: US Stock Futures Slightly Lower Ahead Of Earnings, Fed Speakers
Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade, after recording losses in the earlier session ... 
Tags Pre/Market Outlook Benzinga BKE
From Benzinga
European stocks inch up, while U.S. futures fall on virus headlines and spending spat between Fed and Treasury
European stocks were poised for modest weekly gains, but a lackluster session on Friday as investors absorbed more downbeat news on the virus and a spat between the Treasury and Federal Reserve over... 
Tags NQ00 YM00 IE:SK3
From MarketWatch
Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19
Eli Lilly And Co’s (NYSE: LLY) rheumatoid arthritis drug baricitinib has been issued an emergency use authorization, in ... 
Tags FDA Market News remdesivir
From Benzinga
WHO Advises Against Gilead's Remdesivir For COVID-19 Despite FDA Approval
The United NationsWorld Health Organization said Thursday that Gilead Sciences Inc’s (NASDAQ: GILD) remdesivir is not ... 
Tags remdesivir The Wall Street Journal Market News
From Benzinga
WHO advisers recommend against Gilead’s remdesivir for treating COVID-19
Shares of Gilead Sciences Inc. fell in after-hours trading Thursday after a World Health Organization panel recommended against doctors using the drug remdesivir to treat coronavirus patients. 
Tags GILD
From MarketWatch
Sorrento CEO Henry Ji on How the Company Got Its Start
The company's focus on antibodies helped it pivot into COVID-19. 
Tags MRK KMB Market News
From Motley Fool
Is Moderna Still a Compelling Growth Play?
The biotech might have hit a near-term top. But its future remains as bright as ever. 
Tags GILD PFE BNTX
From Motley Fool
Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV
Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in... 
From Business Wire News Releases
Market Briefing For Tuesday, Nov.17
Frenetic debates about the logic (or lack of) regarding the S&P upside are just a bit numerous. First of all we've only cutback a bit, argued defensive mentally but 'not' short-selling, and on the... 
Tags Pharma/Biotech Stocks / Equities Technology
From Blogs - TalkMarkets
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo... 
From Business Wire News Releases
Gilead's Coronavirus Treatment Questioned By Top Intensive Care Doctor
Gilead's coronavirus treatment, Veklury, shouldn't be used routinely in critically ill patients, according to a top intensive care doctor. Gilead stock has been on a downtrend since July. 
From Investor's Business Daily
Analysts See 10% Gains Ahead For JKF
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Notable ETF Inflow Detected - IBB, AMGN, GILD, REGN
Symbols mentioned in this story: IBB, AMGN, GILD, REGN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
Is There A Light At The End Of The Tunnel For A COVID-19 Therapeutic?
The corporate culture of CytoDyn Inc. has created an atmosphere where management is now able to realize the full potential of a drug that was essentially tossed in the garbage heap. 
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
Why Eli Lilly's Coronavirus Drug Authorization Is Bad News For A Key Rival
Eli Lilly stock jumped Tuesday after the FDA granted its coronavirus treatment emergency authorization. But the news hurts rival Regeneron Pharmaceuticals, which has an antibody cocktail. 
From Investor's Business Daily
These are the non-pharma winners and losers from the Pfizer vaccine results
The 7 most important takeaways for investors. 
Tags CTXS INO SRNE
From MarketWatch
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback